Yahoo! Finance: Biotechnology Industry News: ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Want new traffic sources? Download a copy of our complimentary eBook today, and read about sources that most marketers are not aware of. From our sponsors

ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer Sep 28th 2013, 09:30 [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced updated clinical results on its investigational tyrosine kinase inhibitor , AP26113, in patients with advanced non-small cell lung cancer from an ongoing Phase 1/2 trial.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions